China Factory for 2019 Ncov Novel Coronavirus Test Kit - Heart-type Fatty Acid Binding Protein (H-FABP) – Joinstar

Short Description:

Product Detail

Product Tags

Our organization insists all along the quality policy of "product quality is base of business survival; purchaser gratification is the staring point and ending of an business; persistent improvement is eternal pursuit of staff" as well as the consistent purpose of "reputation 1st, purchaser first" for Sars-Cov-2 Antigen Rapid Covid Test Kit, Covid-19 Igm/Igg Test Kit(Colloidal Gold), Respiratory Adenovirus Antigen, We warmly welcome customers from all over the world for any kind of cooperation with us to build a mutual benefit future. We are devoting ourselves wholeheartedly to offer customers the best service.

China Factory for 2019 Ncov Novel Coronavirus Test Kit - Heart-type Fatty Acid Binding Protein(H-FABP) –JoinstarDetail:

Kit Name: Joinstar Heart-type Fatty Acid Binding Protein Detection Kit

Method: Fluorescence dry quantitative immunoassay

Assay measuring range: 1.0 ng/mL~120.0 ng/mL

Incubation time: 15min

Sample: Human serum, plasma (EDTA anticoagulant), whole blood (EDTA anticoagulant)

Reference range: <6.5 ng/mL

Storage and Stability:

✭Detection Buffer is stable for 12 months at 2°C ~8°C.

✭Sealed Test Device is stable for 12 months at 4°C～30°C.

•Heart-type fatty acid binding protein (H-FABP) was first identified in 1988. It consists of 132 amino acids with a molecular weight of 15 kDa.
•H-FABP is highly expressed in myocardial tissues, and the amount in skeletal muscle is only 10-30% of that in cardiac muscle, and most of it is cleared rapidly by the kidney.
•After onset of myocardial injury, H-FABP increases in 0-3 h, peaks in 6-8 h, and returns to normal in 12-24 h. Its level correlates positively with the extent of myocardial injury.

•《Expert consensus on the use of combined myeloperoxidase, heart-type fatty acid binding protein and cardiac troponin I assays in acute coronary syndrome(2018)》
H-FABP is a cardiac marker that reflects myocardial cell injury and is highly cardiac specific, which can be used for early warning and diagnosis of acute myocardial Infarction (AMI) within 1~3 h of AMI onset.
•《Expert consensus on combined biomarker testing for acute non-traumatic chest pain（2015）》
The metabolic kinetics of early release and rapid excretion of H-FABP are similar to those of Myo, but its myocardial specificity is significantly higher than that of Myo. Combined detection of H-FABP with cTn and CK-MB will be an ideal choice for clinical diagnosis and treatment of ischemic heart disease in a reasonable complementary time window.

•Early diagnosis of acute myocardial infarction (AMI)
H-FABP reaches its peak 7~9 h earlier than cardiac troponin I (cTnI) and creatine kinase isoenzyme (CK-MB), which can rapidly diagnose and exclude AMI.
•Assessment of the size of myocardial ischemic injury
H-FABP levels are positively correlated with myocardial infarct size, and measurement of plasma H-FABP within 24 h of the onset of AMI can effectively assess the size of the infarct.
•Acute myocardial infarction (AMI) recurrence monitoring
After the occurrence of AMI, H-FABP can be significantly increased within 0~3 h and can be completely excreted by the kidneys within 12~24 h. The level of H-FABP in the blood can quickly return to normal. Therefore, monitoring the H-FABP level can predict the occurrence of the second AMI at an early stage.
•Monitoring of myocardial injury caused by cardiac surgery
H-FABP can be detected at the early stage of perioperative myocardial injury and has significant correlation with CK-MB and cTnI, which can improve the accuracy of early diagnosis of perioperative myocardial injury in cardiac surgery.
•Advantages of combined detection of markers of myocardial injury
Myocardial injury markers differ in kinetic characteristics, diagnostic performance and key properties. Therefore, combined testing of multiple indicators is recommended.